FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING

An SI Board Since September 1999

Posts	SubjectMarks	Bans	Symbol
75	8	0	BTK.X

Emcee: opalapril	Type: Unmoderated

Introduction Market Data Compact

In the wake of several spectacular P-3 experimental drug failures, some investors (me, for example) have concluded there is little difference between rank gambling and investing in thinly-capitalized biotechnology companies with nothing but a good story and a literate PR department. Past and present FDA practice compels such entites to endure years of expensive P-1, P-2, and P-3 tests, all the while enabling them to dilute shareholder value with toxic convertibles, secondary issues, and magnanimous options for executives, board members, and their buddies. This thread is intended to help minimize by risk by limiting discussion to companies with promising compounds or medical devices that are on the very threshhold of FDA approval.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
75	Opal, Within moments of finishing my previous post I came up with a new idea fo	Edscharp	-	6/5/2004
74	Opal, Don't know if you're still around, but I've concluded that th	Edscharp	-	6/4/2004
73	Ed, After the market close today, BTRN announced a shelf registration for 5M sha	Arthur Radley	-	12/10/2001
72	Tex, I checked BTRN's news. I hate to be overly cynical, but BTRN sounds e	Edscharp	-	12/10/2001
71	Ed, Let me put it this way! At a certain location, it apparently is deep enough	Arthur Radley	-	12/10/2001
70	So Tex, How deep goes your brazos? Are they in P3 trials yet? ;- )	Edscharp	-	12/10/2001
69	Ed, You certainly can't fault your approaching to investing in biotechs...by	Arthur Radley	-	12/10/2001
68	Tex, Thanks for the tip on BTRN, but I'm not so sure I agree with you. Fir	Edscharp	-	12/9/2001
67	Ed, IMO the way to play MEDI is through BTRN. I expect good news on their psoria	Arthur Radley	-	12/9/2001
66	Opal, Good point. Nonetheless, I think I'm going to stick to my strategy o	Edscharp	-	12/7/2001
65	Actually, I think it is more than coincidence. Didn't the same thing happen	opalapril	-	12/6/2001
64	Hi Opal, We haven't talked in a long while. Hope you are well. I think I s	Edscharp	-	12/6/2001
63	<i>"it is raining cats and dogs here. What would you call that if you	opalapril	-	1/25/2001
62	Dear Mr. Opala Pril, it is raining cats and dogs here. What would you call that	aknahow	-	1/24/2001
61	Dear Mr. Opala Pril, By now I am sure you have seen that XOMA was the second be	aknahow	-	1/1/2001
60	Parking Biotech Industry to Benefit From New Drugs Next Year: Outlook 12/27/200	opalapril	-	1/1/2001
59	VYSI biz.yahoo.com Thursday November 30, 8:30 am Eastern Time Press Release SO	opalapril	-	12/1/2000
58	FDA Action Letter Received in Advance of Ten-Month Review Period biz.yahoo.com	opalapril	-	5/18/2000
57	Texas Biotech - July FDA action expected. Message 13711832	opalapril	-	5/15/2000
56	I'd be careful. BSDM's press release is a lot rosier than Lancet's	opalapril	-	3/31/2000
55	Success of BSD-2000 as lead article in The Lancet ****************************	Micro-Selector	-	3/31/2000
54	ALOHA HERE IS ONE FOR YOU AVNR YEAR AFTER YEAR FDA MORE TEST MORE TEST WILL HA	william prideaux	-	2/25/2000
53	TXB Texas Biotech anticlotting drug approvable HOUSTON, Feb 22 (Reuters) - T	opalapril	-	2/22/2000
52	Message 12862379	opalapril	-	2/16/2000
51	Message 12558812	opalapril	-	2/16/2000

Go to reply# or date (mm/dd/yy):